Venrock Healthcare Capital Partners III, L.P., 10% Owner at KalVista Pharmaceuticals, Inc. (KALV), sold 214,631 shares at $16.95 ($3.7M) on 2026-03-25, disclosed to the SEC on 2026-03-27.
Open-market sale of $3.7M KALV by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.95 | 174,485 | $3.0M | 80.1% |
| 2 | $17.53 | 160 | $3K | 0.1% |
| 3 | $17.76 | 21,386 | $380K | 10.3% |
| 4 | $18.82 | 15,417 | $290K | 7.9% |
| 5 | $19.12 | 3,183 | $61K | 1.6% |
| Total | $17.20 avg | 214,631 |
| $3.7M |
| 100% |
| Filing → |
| KALV | BUY | 2024-01-29 | $1.4M | — | Filing → |
| KALV | BUY | 2024-01-10 | $2.8M | — | Filing → |
| UMRX | BUY | 2020-08-18 | $1.4M | — | Filing → |